An excellent summary of the latest CROWN study results. 7 years in, Lorlatinib still hasn't reached median PFS (the point at which 50% of patients in the Lorlatinib arm of the trial have progressed). alknowledge.org/latest-news/...
alknowledge.org
Latest News - ALK